Weller F R, Weller H H, Kallenberg C G, The T H, Orie N G
J Allergy Clin Immunol. 1986 Sep;78(3 Pt 1):423-30. doi: 10.1016/0091-6749(86)90028-x.
The role of endogenous hydrocortisone in the regulation of lymphocyte activity was assayed in patients with asthma (patients with chronic nonspecific lung disease, characterized by attacks of dyspnea, alternating with symptom-free periods) and healthy control subjects. After priming, delayed-type hypersensitivity skin reactions were induced with Helix pomatia hemocyanin (HPH). Hydrocortisone blood levels were measured. The effect of hydrocortisone on HPH-induced lymphocyte proliferation was determined in vitro. The results demonstrate that hydrocortisone in low concentrations (100 ng/ml) inhibited in vitro lymphocyte proliferation equally in patients and control subjects. However, both groups demonstrated a large interindividual variation in hydrocortisone sensitivity. Therefore, in order to determine the immunologic effect of hydrocortisone blood levels in vivo, a hydrocortisone suppression index (HSI) was calculated by use of the information on hydrocortisone concentrations in vivo and the biologic effect of hydrocortisone in vitro. This HSI appeared to be inversely related with the in vivo cell-mediated immune response to HPH. This was reflected in an inverse correlation between HSI and delayed-type hypersensitivity skin reactions to HPH, both in patients (R = -0.64), in control subjects (R = -0.69), and in the total group (R = -0.68; p less than 0.001). No differences were observed between patients and control subjects. It is concluded that endogenous hydrocortisone is likely to play an important role in the regulation of lymphocyte activity in patients with asthma and healthy control subjects. This may have important consequences for the clinical expression of asthmatic symptoms, since the role of lymphocyte activity in the pathogenesis of asthma is increasingly recognized.
对哮喘患者(患有慢性非特异性肺部疾病,其特征为呼吸困难发作,与无症状期交替出现)和健康对照受试者测定内源性氢化可的松在调节淋巴细胞活性中的作用。在进行激发后,用苹果螺血蓝蛋白(HPH)诱导迟发型超敏皮肤反应。测量氢化可的松的血药浓度。在体外确定氢化可的松对HPH诱导的淋巴细胞增殖的影响。结果表明,低浓度(100 ng/ml)的氢化可的松在患者和对照受试者中均能同等程度地抑制体外淋巴细胞增殖。然而,两组在氢化可的松敏感性方面均表现出较大的个体差异。因此,为了确定体内氢化可的松血药浓度的免疫效应,利用体内氢化可的松浓度信息和氢化可的松的体外生物学效应计算了氢化可的松抑制指数(HSI)。该HSI似乎与体内对HPH的细胞介导免疫反应呈负相关。这体现在患者(R = -0.64)、对照受试者(R = -0.69)以及整个组(R = -0.68;p < 0.001)中HSI与对HPH的迟发型超敏皮肤反应之间的负相关。患者和对照受试者之间未观察到差异。得出的结论是,内源性氢化可的松可能在哮喘患者和健康对照受试者的淋巴细胞活性调节中起重要作用。这可能对哮喘症状的临床表现产生重要影响,因为淋巴细胞活性在哮喘发病机制中的作用日益受到认可。